With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
In buying a company previously thought of as a competitor GTX hopes to dominate the spinal cord injury space.
Instead of tinkering with early-stage genome editing deals like this week's agreement with Bluebird, Novo Nordisk should make a decisive move in haemophilia.